Holen Sie sich die Stockscreener-App
4.49
9.51%
0.39
Handel nachbörslich:
4.41
-0.08
-1.78%
Psyence Biomedical Ltd Aktie (PBM) Neueste Nachrichten
PBM News | PSYENCE BIOMEDICAL LTD (NASDAQ:PBM) - ChartMill
PBM Stock Chart | PSYENCE BIOMEDICAL LTD (NASDAQ:PBM) - ChartMill
$Psyence Biomedical (PBM.US)$ picked me up lets goooo - Moomoo
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing - marketscreener.com
PBM Stock Price, Quote & Chart | PSYENCE BIOMEDICAL LTD (NASDAQ:PBM) - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
TradingKey - TradingKey
Is Psyence (PBMWW) stock hiding in plain sight? (+6.50%) 2026-05-08Theta Decay - newser.com
Psyence Biomedical Ltd. Common Shares (PBM) Live Share Price, Invest From India - INDmoney
12 Health Care Stocks Moving In Friday's Pre-Market SessionAkanda (NASDAQ:AKAN), Akari Therapeutics (N - Benzinga
PBM Forecast, Price Target & Analyst Ratings | PSYENCE BIOMEDICAL LTD (NASDAQ:PBM) - ChartMill
Psyence Biomedical shares rise following equity investment agreement - MSN
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Why is Psyence Biomedical stock falling Wednesday? - MSN
Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market - Moomoo
Psyence Biomedical doses first patient in psilocybin cancer trial By Investing.com - Investing.com Australia
PBM jumps on Trump psychedelic push, ibogaine supply story - MSN
Psyence BioMed Begins Phase IIb Dosing of Psilocybin Candidate NPX-5 in Australian Cancer Adjustment Disorder Trial - TipRanks
Psyence BioMed (Nasdaq: PBM) doses first patient in NPX-5 Phase IIb trial - Stock Titan
Why Is Psyence Biomedical Stock Falling Wednesday? - Sahm
Psyence Biomedical doses first patient in psilocybin cancer trial - Investing.com
Psyence Biomedical (PBM) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder - The Manila Times
Psyence Biomedical Ltd. Begins Phase IIb Clinical Trial for NPX-5 Psilocybin Treatment in Cancer Patients - Quiver Quantitative
PBMWW Psyence highlights clinical trial progress as core strategic priority in its latest quarterly earnings release.Community Watchlist - Cổng thông tin điện tử Tỉnh Sơn La
Why is Psyence Biomedical stock trading lower on Tuesday? - MSN
Psyence Biomedical Ltd.Common Shares (NQ:PBM) - FinancialContent
Psyence Biomedical Ltd - Reuters
Psyence Biomedical Tumbles On Heels Of Trump Executive OrderPsyence Biomedical (NASDAQ:PBM) - Benzinga
$Psyence Biomedical (PBM.US)$ hope i timed a good entry on this one - Moomoo
Psyence Biomedical Adds Intraday Equity Purchase Option in White Lion Financing Deal - The Globe and Mail
PBM Stock Trips Into Spotlight Again: Rare Ibogaine Supply Edge Gets Boost From Trump’s Psychedelic Push - Stocktwits
Is Psyence (PBM) stock a suitable buy candidate (Soars) 2026-04-20Certified Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Top Small Cap Stocks To Keep An Eye OnApril 20th - MarketBeat
Trending Stocks Today | Enveric Biosciences Surges 115.38% - Moomoo
What's going on in today's session - ChartMill
Psyence (PBMWW) Stock: Support and Resistance (Technical Strength) 2026-04-20Most Discussed Stocks - UBND thành phố Hải Phòng
PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story - Benzinga
These stocks are gapping in today's session - ChartMill
Psyence Biomedical provides update on position in global ibogaine market - TipRanks
$Psyence Biomedical (PBM.US)$ I'm definitely out now. Had to go for one last dip of the Honey pot.🍯 - Moomoo
Top movers in Monday's pre-market session - ChartMill
Morning Market Movers: ENVB, PBM, PASG, ATAI See Big Swings - RTTNews
Psyence Biomedical (PBM) adds intraday stock sale option with White Lion - Stock Titan
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):